Document Detail


Multidrug-resistant tuberculosis.
MedLine Citation:
PMID:  23190230     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To the Editor: The study by Gler et al. (June 7 issue)(1) provides a needed reminder regarding the development pipeline for drugs for tuberculosis and multidrug-resistant (MDR) tuberculosis.(2) Delamanid with bedaquiline is increasing the potential for improving current regimens for tuberculosis. In their editorial in the same issue, Chaisson and Nuermberger(3) go one step further, posing the question of how these drugs should be used and highlighting the need for combination trials to maximize effectiveness and minimize negative drug interactions among new drugs for tuberculosis. These issues are of key importance. Knowing the complexity of tuberculosis control and the difficulty . . .
Authors:
Shua J Chai; Carol Y Rao; Jay K Varma
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  367     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2154-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multidrug-resistant tuberculosis.
Next Document:  Multidrug-resistant tuberculosis.